Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6680537 | 0.83 | NPY5R (0.47) | AURKAIKBKB | |
| SCHEMBL6679169 | 0.82 | KDM4E (0.47) | AURKAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6676384 | 0.82 | HDAC3 (0.39) | PDE4BAURKAHDAC3HDAC4HDAC1 | |
| SCHEMBL6677271 | 0.79 | HDAC3 (0.41) | PDE4BAURKAHDAC3HDAC4HDAC1 | |
| SCHEMBL25208697 | 0.76 | ALDH1A1 (0.45) | — | |
| SCHEMBL5118511 | 0.74 | MERTK (0.47) | — | |
| SCHEMBL5107999 | 0.71 | KMT2A (0.49) | — | |
| SCHEMBL5450923 | 0.70 | IDO1 (0.46) | — | |
| SCHEMBL3771108 | 0.69 | ALDH1A1 (0.61) | PDE4B | |
| SCHEMBL5104884 | 0.69 | KDM1A (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | PDE4B 3705/4885AURKA 2051/4885HDAC3 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.